AFM26 targets BCMA and CD16A and induces effective lysis of primary myeloma cells in vitro, independent of CD16A polymorphism and not limited by the low copy number of BCMA (Ross et al., 2018). This evidence concerns the gene FCGR3A and plasma cell myeloma.